Activation of apoptosis pathways by anticancer treatment

Toxicology Letters

Volumn 112-113, Issue , 2000, Pages 41-48

  Debatin, Klaus Michael ^a  

^a UNIVERSITY HOSPITAL ULM   (Germany)

Author keywords

Apoptosis; Caspases; CD95 system; Chemotherapy; Mitochondrial alterations; Signal pathways

Indexed keywords

ANTINEOPLASTIC AGENT; CASPASE; FAS ANTIGEN; NERVE GROWTH FACTOR; PROTEIN P53; TUMOR NECROSIS FACTOR;

APOPTOSIS; CANCER; CANCER CHEMOTHERAPY; CELL ACTIVATION; CONFERENCE PAPER; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DRUG SENSITIVITY; ENZYME ACTIVATION; HUMAN; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CASPASES; ENZYME INDUCTION; FAS LIGAND PROTEIN; HUMANS; MEMBRANE GLYCOPROTEINS; MITOCHONDRIA; SIGNAL TRANSDUCTION;

EID: 0034654326     PISSN: 03784274     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0378-4274(99)00252-0     Document Type: Conference Paper

References (54)

1. Aragane Y., Kulms D., Metze D., Wilkes G., Pöppelmann B., Luger T.A., Schwarz T. Ultraviolet light induces apoptosis via direct activation of CD95 (Fas/APO-1) independently of its ligand CD95L. J. Cell Biol. 140:1998;171-182.
2. Ashkenazi A., Dixit V.M. Death receptors: signaling and modulation. Science. 281:1998;1305-1308.
3. Bauer M.K.A., Vogt M., Los M., Siegel J., Wesselborg S., Schulze-Osthoff K. Role of reactive oxygen intermediates in activation-induced CD95 (APO-1/FAS) ligand expression. J. Biol. Chem. 273:1998;8048-8055.
4. Beltinger C.P., Kurz E., Böhler T., Schrappe M., Ludwig W.D., Debatin K.M. CD95 (APO-1/FAS) mutations in childhood T-lineage acute lymphoblastic leukemia. Blood. 91:1998;3943-3951.
5. Bennet M., MacDonald K., Chan S.W., Luzio J.P., Simari R., Weissberg P. Cell surface trafficking of FAS: a rapid mechanism of p53-mediated apoptosis. Science. 282:1998;290-293.
6. Bose R., Verheij M., Haimovitz-Friedman A., Scotto K., Fuks Z., Kolesnick R. Ceramide synthase mediates daunorubicin-induced apoptosis: an alternative mechanism for generating death signals. Cell. 82:1995;405-414.
7. Campos L., Rouault J.P., Sabido O., Oriol P., Roubi N., Vasselon C., Archimbaud E., Magaud J.P., Guyotat D. High expression of Bcl-2 protein in acute myeloid leukemia cells is associated with poor response to chemotherapy. Blood. 81(11):1993;3091-3096.
8. Debatin K.M. Disturbances of the CD95 (APO-1/FAS) system in disorders of lymphohematopoietic cells. Cell Death Diff. 3:1996;185-189.
9. Debatin K.M., Goldman C.K., Bamford R., Waldmann T.A., Krammer P.H. Monoclonal antibody-mediated apoptosis in adult T-cell leukemia. Lancet. 335:1990;497-500.
10. Debatin K.M., Krammer P.H. Resistance to APO-1 (CD95) induced apoptosis in T-ALL is determined by a Bcl-2 independent anti-apoptotic program. Leukemia. 9:1995;815-820.
11. Debatin K.M. Cytotoxic drugs, programmed cell death, and the immune system: defining new roles in an old play. J. Nat. Cancer Inst. 89:1997;750-751.
12. Dhein J., Walczak H., Bäumler C., Debatin K.M., Krammer P.H. Autocrine T-cell suicide mediated by APO-1/FAS (CD95). Nature. 373:1995;439-441.
13. Eischen C.M., Kottke T.J., Martins L.M., Basi G.S., Tung J.S., Earnshaw W.C., Leibson P.J., Kaufmann S.H. Comparison of apoptosis in wild-type and Fas-resistant cells: chemotherapy-induced apoptosis is not dependent on Fas/Fas ligand interactions. Blood. 90(3):1997;935-943.
14. Faris M., Kokot N., Latinis K., Kasibhatla S., Green D.R., Koretzky G.A. The c-Jun N-terminal kinase cascade plays a role in stress-induced apoptosis in Jurkat cells by up-regulating FAS ligand expression. J. Immunol. 160:1998;134-144.
15. Fisher G.H., Rosenberg F.J., Straus S.E., Dale J.K., Middelton L.A., Lin A.Y., Strober W., Lenardo M.J., Puck J.M. Dominant interfering fas gene mutations impair apoptosis in a human autoimmune lymphoproliferative syndrome. Cell. 81:1995;935-946.
16. Friesen C., Herr I., Krammer P.H., Debatin K.M. Involvement of the CD95 (APO-1/FAS) receptor/ligand system in drug-induced apoptosis in leukemia cells. Nature Med. 2:1996;574-577.
17. Friesen C., Fulda S., Debatin K.M. Deficient activation of the CD95 (APO-1/FAS) system in drug resistant cells. Leukemia. 11:1997;1833-1841.
18. Fulda S., Friesen C., Los M., Scaffidi C.A., Mier W., Benedict M., Nunez G., Krammer P.H., Peter M.E., Debatin K.M. Betulinic acid triggers CD95 (APO-1/Fas)- and p53 independent apoptosis via activation of caspases in neuroectodermal tumors. Cancer Res. 57:1997;4956-4964.
19. Fulda S., Sieverts H., Friesen C., Herr I., Debatin K.M. The CD95 (APO-1/FAS) system mediates drug-induced apoptosis in neuroblastoma cells. Cancer Res. 57:1997;3823-3829.
20. Green D.R., Reed J.C. Mitochondria and apoptosis. Science. 281:1998;1309-1312.
21. Hakem R., Hakem A., Duncan G.S., Henderson J.T., Woo M., Soengas M.S., Elia A., de la Pompa J.L., Kagi D., Khoo W., Potter J., Yoshida R., Kaufmann S.A., Lowe S.W., Penninger J.M., Mak T.W. Differential requirement for caspase-9 in apoptotic pathways in vivo. Cell. 94:1998;339-352.
22. Hannun Y.A. Apoptosis and the dilemma of cancer chemotherapy. Blood. 89:1997;1845-1853.
23. Herr I., Böhler T., Wilhelm D., Angel P., Debatin K.M. Activation of CD95 (APO-1/FAS) signaling by ceramide mediates cancer therapy-induced apoptosis. EMBO J. 16:1997;6200-6208.
24. Honglin L., Hong Z., Chi-jie X., Junying Y. Cleavage of BID by caspase-8 mediates the mitochondrial damage in the Fas pathway of apoptosis. Cell. 94:1998;491-501.
25. Houghton J.A., Harwood F.G., Tillman D.M. Thymineless death in colon carcinoma cells is mediated via FAS signaling. Proc. Natl. Acad. Sci. USA. 94:1997;8144-8149.
26. Hueber A.O., Zörnig M., Lyon D., Suda T., Nagata S., Evan G.I. Requirement for the CD95 receptor-ligand pathway in c-myc-induced apoptosis. Science. 278:1997;1305-1309.
27. Kasibhatla S., Brunner T., Genestier L., Echeverri F., Mahboubi A., Green D.R. DNA damaging agents induce expression of FAS ligand and subsequent apoptosis in T lymphocytes via the activation of NFκB and AP-1. Mol. Cell. 1:1998;543-551.
28. Krajewski S., Blomqvist C., Franssila K., Krajewska M., Wasenius V.M., Niskanen E., Nordling S., Reed J.C. Reduced expression of pro-apoptotic gene bax is associated with poor response rates to combination chemotherapy and shorter survival in women with metastatic breast adenocarcinoma. Cancer Res. 55:1995;4471-4478.
29. Krammer P.H., Dhein J., Walczak H., Behrmann I., Mariani S., Matiba B., Fath M., Daniel P.T., Knipping E., Westendorp M.O., Stricker K., Bäumler C., Hellbardt S., Germer M., Peter M.E., Debatin K.M. The role of APO-1 mediated apoptosis in the immune system. Immunol. Rev. 142:1994;175-191.
30. Kroemer G. The proto-oncogene Bcl-2 and its role in regulating apoptosis. Nature Med. 3:1997;614-620.
31. Kuida K., Haydar T.F., Kuan C.Y., Gu Y., Taya C., Karasuyama H., Su M.S., Rakic P., Flavell R.A. Reduced apoptosis and cytochrome c-mediated caspase activation in mice lacking caspase-9. Cell. 94:1998;325-337.
32. Levine A.J. p53, the cellular gatekeeper for growth and division. Cell. 88:1997;323-331.
33. Lowe S.W., Ruley H.E., Jacks T., Housman D.E. p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell. 74:1993;957-967.
34. Lowe S.W., Bodis S., McClatchey A., Remington L., Ruley H.E., Fisher D.E., Housman D.E., Jacks T. p53 status and the efficacy of cancer therapy in vivo. Science. 266:1994;807-810.
35. Luoo X., Budihardjo I., Zou H., Slaughter C., Wang X. Bid, Bcl-2 interacting protein, mediates cytochrome c release from mitochondria in response to activation of cell surface death receptors. Cell. 94:1998;481-490.
36. Micheau O., Solary E., Hammann A., Martin F., Dimanche-Boitrel M.T. Sensitization of cancer cells treated with cytotoxic drugs to FAS-mediated cytotoxicity. J. Nat. Cancer Inst. 89:1997;783-789.
37. Milner J. DNA damage, p53 and anticancer therapies. Nature Med. 1:1995;879-880.
38. Min Y.H., Lee S., Lee J.W., Chong S.Y., Hahn J.S., Ko Y.W. Expression of FAS antigen in acute myeloid leukemia is associated with therapeutic response to chemotherapy. Br. J. Haematol. 93:1996;928-930.
39. L can confer a multidrug resistance phenotype. Blood. 86:1995;1903-1910.
40. Müller M., Strand S., Hug H., Heinemann E.M., Walczak H., Hofmann W.J., Stremmel W., Krammer P.H., Galle P. Drug-induced apoptosis in hepatoma cells is mediated by the CD95 (APO-1/Fas) receptor/ligand system and involves activation of wild-type p53. J. Clin. Invest. 99:1997;403-413.
41. Nagata S., Golstein P. The FAS death factor. Science. 267:1995;1449-1456.
42. Nagata S. Apoptosis by death factor. Cell. 88:1997;355-365.
43. Newton K., Harris A.W., Bath M.L., Smith K.G.C., Strasser A. A dominant interfering mutant of FADD/MORT1 enhances deletion of autoreactive thymocytes and inhibits proliferation of mature T lymphocytes. EMBO J. 17:1998;706-718.
44. Owen-Schaub L.B., Zhang W., Cusack J.C., Angelo L.S., Santee S.M., Fujiwara T., Roth J.A., Deisseroth A.B., Zhang W.W., Kruzel E., Radinsky R. Wild-type human p53 and a temperature-sensitive mutant induce Fas/APO-1 expression. Mol. Cell Biol. 15(6):1995;3032-3040.
45. l form a ternary complex. J. Biol. Chem. 273:1998;5841-5845.
46. Reap E.A., Roof K., Maynor K., Borrero M., Booker J., Cohen P.L. Radiation and stress-induced apoptosis: a role for FAS/FAS ligand interactions. Proc. Natl. Acad. Sci. USA. 94:1997;5750-5755.
47. Rehemtulla A., Hamilton C.A., Chinnaiyan A.M., Dixit V.M. Ultraviolet radiation-induced apoptosis is mediated by activation of CD95 (FAS/APO-1). J. Biol. Chem. 272(41):1997;25783-25786.
48. Rieux-Laucat F., Le Deist F., Hivroz C., Roberts I.A.G., Debatin K.M., Fischer A., De Villartay J.P. Mutations in Fas associated with human lymphoproliferative syndrome and autoimmunity. Science. 268:1995;1347-1349.
49. Scaffidi C., Fulda S., Srinivasan A., Friesen C., Li F., Tomaselli K.J., Debatin K.M., Krammer P.H., Peter M.E. Two CD95 (APO-1/Fas) signaling pathways. EMBO J. 17:1998;1675-1687.
50. Varfolomeev E.E., Schuchmann M., Luria V., Chiannilkulchai N., Beckmann J.S., Mett I.L., Rebrikov D., Brodianski V.M., Kemper O.C., Kollet O., Lapidot T., Soffer D., Sobe T., Avraham K.B. Targeted disruption of the mouse caspase-8 gene ablates cell death induction by the TNF receptors, FAS/APO-1 and DR3 and is lethal prenatally. Immunity. 9:1998;267-276.
51. Villunger A., Egle A., Kos M., Hartmann B., Geley S., Kofler R., Greil R. Drug-induced apoptosis is associated with enhanced Fas (APO-1/CD95) ligand expression but occurs independently of Fas (APO-1/CD95) signaling in human T-acute lymphatic leukemia cells. Cancer Res. 57:1997;3331-3334.
52. Yeh W.C., de la Pompa J.L., McCurrach M.E., Shu H.B., Elia A.J., Shahinian A., Ng M., Wakeham A., Khoo W., Mitchell K., El-Deiry W.S., Lowe S.W., Goeddel D.V., Mak T.W. FADD: essential for embryo development and signaling from some, but not all, inducers of apoptosis. Science. 279:1998;1954-1958.
53. Yoshida H., Kong Y.Y., Yoshida R., Elia A.J., Hakem A., Hakem R., Penninger J.M., Mak T.W. Apaf-l is required for mitochondrial pathways of apoptosis and brain development. Cell. 94:1998;739-750.
54. Yoshihiro K., Zhou Y.W., Zhang X.L., Chen T.X., Tanaka S., Azuma E., Sakurai M. Fas/APO-1 (CD95)-mediated cytotoxicity is responsible for the apoptotic cell death of leukaemic cells induced by interleukin-2-activated T cells. Br. J. Haematol. 96:1997;147-157.